TY - JOUR T1 - A method for the generation of pseudotyped virus particles bearing SARS coronavirus spike protein in high yields JF - bioRxiv DO - 10.1101/2021.07.30.454063 SP - 2021.07.30.454063 AU - Yoichiro Fujioka AU - Sayaka Kashiwagi AU - Aiko Yoshida AU - Aya O. Satoh AU - Mari Fujioka AU - Maho Amano AU - Yohei Yamauchi AU - Yusuke Ohba Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/07/30/2021.07.30.454063.abstract N2 - The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has threatened human health and the global economy. Development of additional vaccines and therapeutics is urgently required, but such development with live virus must be conducted with biosafety level 3 confinement. Pseudotyped viruses have been widely adopted for studies of virus entry and pharmaceutical development to overcome this restriction. Here we describe a modified protocol to generate vesicular stomatitis virus (VSV) pseudotyped with SARS-CoV or SARS-CoV-2 Spike protein in high yield. We found that pseudovirions produced with the conventional transient expression system lacked coronavirus Spike protein at their surface as a result of inhibition of parental VSV infection by overexpression of this protein. Establishment of stable cell lines with an optimal expression level of coronavirus Spike protein allowed the efficient production of progeny pseudoviruses decorated with Spike protein. This improved VSV pseudovirus production method should facilitate studies of coronavirus entry and development of antiviral agents.Competing Interest StatementThe authors have declared no competing interest. ER -